Republic Republic Republic
  • Log in
Open account
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Trading Buy and sell Republic Note Own a piece of Republic's upside
Republic Ventures Opportunities for accredited investors
Republic Capital Multi-stage venture firm
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward Founder Academy A complete guide to raising funds
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US

  • Log in
  • Open account
All investors
Primary market Live deals Trading Buy and sell
Republic Note Own a piece of Republic's upside
Accredited only
Republic Ventures Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward Founder Academy A complete guide to raising funds
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets
Tokenization Deploy your assets on-chain
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services

Responsum Health isn't accepting new investments

Responsum Health’s deadline was March 27, 2022

Follow the company to stay updated on their progress, including future investment opportunities


Explore new investment opportunities:
View companies raising now
Campaign ended
Logo of Responsum Health

Responsum Health

Building online knowledge communities for people with chronic conditions
B2B SaaS Healthcare
Facebook Telegram Twitter LinkedIn
Featured image of Responsum Health
$130,063
Raised
284
Investors
Successfully funded and closed on March 27, 2022.
Invest in Responsum Health

Open for investment

Investors in Responsum Health also invested in these companies. View more
Logo of  Metaintro

Metaintro

The Bloomberg of Labor Markets - AI-powered workforc...

Republic Funding Portal · Reg CF
Loading...
Pitch Updates 13 Reviews 69
Invest Invest in Responsum Health
Facebook Telegram Twitter LinkedIn
Closed on March 27, 2022. Information may not be up-to-date. Campaign closed on March 27, 2022. Information displayed may not be up-to-date.
Problem Solution Product Traction Customers Biz. model Market Competition Vision and strategy Funding Founder
About Team Press

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Responsum, Inc.. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Responsum Health Crowd SAFE Responsum Health Form C:A.pdf Responsum Form C.pdf
Loading

Hear from some of the 284 investors in Responsum Health


Show more

Highlights


Profitable
Company has been profitable for the past 6 months
  • Disease-specific, web-curated Newsfeeds for people with chronic conditions
  • 4 patient-partnered, commercially supported platforms in the market
  • Just launched platform #5 for persons with Long COVID
  • Participant in StartUp Health Accelerator Program
  • Customers include Otsuka, Abbvie, Galapagos, The Allergan Foundation
  • Profitable w/ $840K in 2020 revenue, monthly revenue of $72.5K (June 2021)
  • Projected revenue of $9M by 2025

Problem


For people with chronic illnesses, there's no place to get trusted, current, and truly comprehensive information about their disease

At some point, virtually every recently diagnosed person goes online to research their condition. But the Internet is a Wild West of information. Patients can easily find themselves overwhelmed, confused, and misled by what they find.  

Pharmaceutical companies also need their patients to be knowledgeable and confident if they are to maintain adherence to their drug regimens.

By convening patients around knowledge and providing them with opportunities to share their lived experiences, Responsum provides its industry partners with an indispensable tool for both supporting and learning from people with chronic illness.

Solution


Building patient knowledge, one community at a time

Responsum creates and manages disease-specific, patient knowledge, and community building apps. Developed from years of research, interviews, and collaboration with patients, our free, disease-specific apps are designed to improve knowledge, grow self-confidence, support needs and concerns, and facilitate the organization and coordination of healthcare information. 

Product


Responsum customizes knowledge platforms for chronic disease patient communities

Patients who use Responsum get a team of professional medical researchers and writers, backed by state-of-the-art technology, to scour, curate, and “translate” the Internet for news, blog posts, discoveries, and lifestyle tips about their chronic disease. Rather than constantly performing their own online research and analysis, patients can rely on Responsum's newsfeed and instead spend their time and energy on living and regaining health.

The Responsum app also includes a highly-active, responsibly-moderated Community Chat where patients and medical professionals share experiences, advice, and support. The app also includes patient-designed data organizing tools, like the Patient One-Sheet, to facilitate their ability to track their care and engage efficiently with their numerous healthcare providers.

Traction


4 patient-partnered, commercially supported platforms in the market            

Launched in 2019, Responsum now has 4 patient-partnered, commercially supported platforms in the market: Pulmonary Fibrosis, Chronic Kidney Disease, Fibroids, and the Glaucoma Community. An additional app for Long COVID patients was launched in March 2021. Born as a Capstone research project at Carnegie Mellon University's Human Computer Interaction Institute in 2014, we were accepted into the StartUp Health Accelerator Program in 2019. We've since engaged in numerous partnerships with leading patient advocacy groups and pharmaceutical companies. Now profitable, we generated $840K in 2020 revenue.

Customers


Pharmaceutical companies can support their patient communities and receive actionable data

Responsum's key customers are pharmaceutical companies. By partnering with us to underwrite a disease-specific knowledge platform, our commercial supporters simultaneously demonstrate their commitment to serving their patients while gleaning valuable insights into the way patients experience and value healthcare. Responsum has also delivered considerable value by recruiting and screening patients from its communities for clinical trials. 

Our patients have an ally on their path to better health

Our apps are carefully designed to keep them informed, connected, and supported. Many of them are reporting positive outcomes from being a Responsum Health member!

Business model


$9M in revenue by 2025

The Responsum Health platform and its services are provided free of charge to all of our users—patients, family members, caregivers, healthcare providers, and medical professionals.

We enter into annual SaaS arrangements with pharmaceutical sponsors of individual platforms or clinical trial recruitment campaigns with gross margins of up to 100% on future platforms. We are now seeing monthly revenue of $72.5K (as of June 2021). In the future, we expect our costs will soon be underwritten by grants from a combination of supporters including foundations, companies, and nonprofits. With our current clients and projected partnership pipeline, we project revenue to reach $9M by 2025.

Market


Our room to grow is virtually limitless

There are thousands of individually identifiable diseases and conditions with 133M+ Americans affected by chronic illness. More patients are turning to the internet as their first source of health information, but misinformation is rampant. The pharmaceutical industry and other stakeholders have a growing imperative to engage, inform, survey, and recruit patients. 

Our go-to-market strategy is to meet with, and sell to, pharmaceutical companies with an interest in supporting patients in a given therapeutic area or gleaning insights from patient surveys, engagement, or trial recruitment. 

Competition


Peer-to-peer engagement with trustworthy content

Responsum curates the Internet daily and provides patients with independently-vetted, disease-specific, keyword-tagged article summaries directly through an engaging app. As far as we can tell, nobody else does this. Our competitors are either companies like Patients Like Me and Inspire, which convene digital patient communities via disease-specific social walls, or online publishers of disease-specific content aimed at patients. Responsum is an industry leader by convening patient group partners and Expert Advisory Councils comprised of patients and medical experts to guide the search, curation, and summary of the Internet for patients with chronic illness.

Vision and strategy


In discussion with Astellas, AstraZeneca, and others to expand our disease app portfolio

Responsum has a clear path of growth for this coming year, which includes launching new Responsum-led platforms and bringing on new partners. Current opportunities under discussion include projects with Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, Astellas, Daichii Sankyo, the National Institutes of Health, and others.

Additionally, the company's recent launch of Responsum for Long COVID presents a unique opportunity to build a multi-sponsored program in this urgently needed area of investment. 

Funding


2 years of jet-fueled growth    

Key areas of development include doubling the number of our platforms, expanding our patient group partnerships, and investing in the expansion of our business development team.

Founder


Andrew Rosenberg

Founded by a serial entrepreneur, whose healthcare-focused government affairs firm ranks among the largest and most successful in Washington, DC,  Responsum Health was borne out of the challenges Andrew Rosenberg faced while attempting to navigate the healthcare system for his ailing mother.  He asked, "if it is so difficult for someone like me - who is so steeped in health policy - to find current, trustworthy, and understandable content for my mom on the Internet, I can't imagine how frustrating this experience must be for others." So Andrew spent the next five years, partnering with a cohort of graduate students at Pittsburgh's Carnegie Mellon University, a team of technology and health experts, and literally hundreds of patients with chronic illness, to develop this revolutionary app and approach to improving patient knowledge. 

Deal terms


Valuation cap

$4,500,000

The maximum valuation at which your investment converts into equity shares or cash.
Learn more

Minimum investment

$100

The smallest investment amount that Responsum Health is accepting.
Learn more

Maximum investment

$100,000

The largest investment amount that Responsum Health is accepting.
Learn more

Funding goal

$1.07M

The maximum amount the offering can raise is $1.07M.
Learn more

Deadline
Responsum Health needs to reach their minimum funding goal before the deadline ( ). If they don’t, all investments will be refunded.
Learn more
Type of security

Crowd SAFE

A SAFE allows an investor to make a cash investment in a company, with rights to receive certain company stock at a later date, in connection with a specific event. · Learn more

How it works

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Responsum, Inc.. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Responsum Health Crowd SAFE Responsum Health Form C:A.pdf Responsum Form C.pdf

Bonus perks

In addition to your Crowd SAFE, you'll receive perks for investing in Responsum Health.
Invest
$100
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
Invest
$250
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
  • Personal Thank You email from CEO, Andrew Rosenberg
  • Appear in listing of key investors on ResponsumHealth.com
Invest
$500
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
  • Personal Thank You email from CEO, Andrew Rosenberg
  • Appear in listing of key investors on ResponsumHealth.com
  • Responsum Health T-Shirt
Invest
$1,000
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
  • Personal Thank You email from CEO, Andrew Rosenberg
  • Appear in listing of key investors on ResponsumHealth.com
  • Responsum Health T-Shirt
  • Responsum Health 20 oz. Yeti Tumbler
Invest
$2,000
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
  • Appear in listing of key investors on ResponsumHealth.com
  • Responsum Health T-Shirt
  • Responsum Health 20 oz. Yeti Tumbler
  • Personal "Thank You" phone call from CEO, Andrew Rosenberg
Invest
$5,000
Receive
  • "Thank you" mention on Responsum Health's Twitter channel
  • Appear in listing of key investors on ResponsumHealth.com
  • Responsum Health T-Shirt
  • Responsum Health 20 oz. Yeti Tumbler
  • Personal quarterly Investor Update phone call from CEO, Andrew Rosenberg

About Responsum Health

Legal Name
Responsum, Inc.
Founded
Jul 2014
Form
Delaware Corporation
Employees
0
Website
responsumhealth.com
Social Media
Headquarters
Google Map location of of Responsum Health
100 M Street, SE STE 750 , Washington, DC
Headquarters
100 M Street, SE, STE 750, Washington, DC, United States 20003

Responsum Health Team
Everyone helping build Responsum Health, not limited to employees

Profile picture of Andrew Rosenberg
Andrew Rosenberg
Founder and CEO
Featured in Superheroes · Read
Andrew has been a Washington, D.C.-based healthcare policy expert for nearly two decades. His vision and relentlessness have fueled Responsum's mission since its development stages.
Profile picture of Yury Salazar Smith
Yury Salazar Smith
Vice President of Operations
Yury has been instrumental in designing, revising, and developing Responsum's systematic approach and proprietary technology since its launch.
Profile picture of Zachary Kay
Zachary Kay
Digital Marketing Director
Profile picture of Sharinda Williams-Simmons
Sharinda Williams-Simmons
Social Media Manager
Profile picture of Bridget Greinke
Bridget Greinke
Community Relations Director
Profile picture of Dominic Nicosia
Dominic Nicosia
Chief Content Editor
Profile picture of Hung Luu
Hung Luu
Chief Technology Officer
Profile picture of Jenny Rosenberg
Jenny Rosenberg
Public Relations Director
Profile picture of Tony Howell
Tony Howell
Senior Advisor
Profile picture of Vanessa Rangel Miller
Vanessa Rangel Miller
Senior Advisor
Profile picture of Thayer Surette Roberts
Thayer Surette Roberts
Senior Advisor
9 more team members
Andrew Rosenberg
Founder and CEO
Zachary Kay
Digital Marketing Director
Sharinda Williams-Simmons
Social Media Manager
Yury Salazar Smith
Vice President of Operations
Bridget Greinke
Community Relations Director
Dominic Nicosia
Chief Content Editor
Hung Luu
Chief Technology Officer
Jenny Rosenberg
Public Relations Director
Tony Howell
Senior Advisor
Vanessa Rangel Miller
Senior Advisor
Thayer Surette Roberts
Senior Advisor

Press

Press Release - Prevent Blindness and Responsum Health An...
Responsum Health
·
Feb 28, 2022

The Glaucoma Community by Prevent Blindness earns 2022 sponsorship from Glaukos and Santen Pharmaceutical [WASHINGTON, D....

Press Release - Responsum Health Named A "Deal to Watch,"...
Responsum Health
·
Jan 27, 2022

The rating places Responsum Health in the top 0.5% out of more than 700 active equity crowdfunding campaigns currently ra...

Cynthia Bailey Addresses Vital Health Issues
Breaking Celebrity News, Entertainment News, and Celebrity Gossip - Celebrity Insider Breaking Celebrity News, Entertainment News, and Celebrity Gossip - Celebrity Insider
·
Apr 26, 2021

Cynthia Bailey is addressing some vital health-related issues these days. Check out her recent post in support of the Res...

Smartphone App to Support COVID-19 Long Haulers (Long COVID)
Policy & Medicine Policy & Medicine
·
Apr 11, 2021

Responsum Health (Responsum), an innovative developer of personalized patient apps and chronic disease knowledge communit...

Responsum Health and IgA Nephropathy Foundation Announce ...
PRWeb PRWeb
·
Dec 3, 2020

"We are excited to partner with Responsum Health. This opportunity will bring valuable information to the patients we ser...

Prevent Blindness and Responsum Health Launch Innovative ...
The International Agency for the Prevention of Blindness The International Agency for the Prevention of Blindness
·
Nov 9, 2020

In an effort to educate the public on glaucoma, raise awareness and bring patients and caregivers together, today, Preven...

New Fibroids App Provides Empowerment, Knowledge, and Sup...
Faith Health and Home Faith Health and Home
·
Aug 16, 2020

Women's Health App Supports Fibroids Community with New Empowerment Platform. Innovative technology provides vetted infor...

Responsum Health Launches Innovative Kidney Disease Infor...
PRWeb PRWeb
·
May 28, 2020

By working with recognized leaders from the patient advocacy community, we have created a trusted online platform that fi...

PF Responsum Health Newsfeed | Pulmonary Fibrosis Foundation
Default Default
·
Jan 23, 2019

CHICAGO, Jan. 23, 2019 - Pulmonary fibrosis patients, their loved ones and care team can now connect through a platform j...

Show all
Logo of Responsum Health

Responsum Health

Responsum Health successfully raised $130,063 from 284 investors on March 27, 2022
Profile picture of Jacob Hanchar
Profile picture of Takashi Sengoku
Profile picture of Dylan Cotter
Profile picture of Mark Peck
Profile picture of Ashok Thysheril
Jacob, Takashi, Dylan, Mark, Ashok, and 279 others invested. 69 Reviews
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Tokenized assets
Company
  • About
  • Insights
  • Events
  • Contact
  • Security
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.

All related securities activity is conducted by OpenDeal Broker LLC a registered broker-dealer, Member of FINRA and SiPC, an affiliate of OpenDeal Inc. and OpenDeal Portal LLC, located at 149 5th Avenue, 10th Floor, New York, NY 10010. Please check our background on FINRA’s BrokerCheck.

Certain pages discussing the mechanics and providing educational materials regarding regulation crowdfunding offerings may refer to OpenDeal Broker LLC and OpenDeal Portal LLC collectively as “Republic”, solely for explanatory purposes.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC make investment recommendations and no communication, through this Site, or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Investment opportunities posted on this Site are private placements of securities that are not publicly traded, involve a high degree of risk, may lose value including the total loss of invested capital, are subject to holding period requirements and are intended for investors who do not need a liquid investment. Past performance is not indicative of future results. Investors must be able to afford the loss of their entire investment. Only qualified investors, who understand the risks of early-stage investment and who meet the Republic's investment criteria may invest. Investors may be restricted to only Accredited Investors or non-U.S. persons, to invest in offerings hosted by OpenDeal Broker. Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC, nor any of their officers, directors, agents and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this Site or the use of information on this site. Offers to sell securities can only be made through official offering documents that contain important information about the investment and the issuers, including risks. Investors should carefully read the offering documents. Investors should conduct their own due diligence and are encouraged to consult with their tax, legal and financial advisors.

By accessing the Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Please also see OpenDeal Broker’s Business Continuity Plan and Additional Risk Disclosures. All issuers offering securities under regulation crowdfunding as hosted by OpenDeal Portal LLC are listed on the All Companies Page. The inclusion or exclusion of an issuer on the Platform Page and/or Republic’s Homepage, which includes offerings conducted under regulation crowdfunding as well as other exemptions from registration, is not based upon any endorsement or recommendation by OpenDeal Inc, OpenDeal Portal LLC, or OpenDeal Broker LLC, nor any of their affiliates, officers, directors, agents, and employees. Rather, issuers of securities may, in their sole discretion, opt-out of being listed on the Platform Page and Homepage.

Investors should verify any issuer information they consider important before making an investment.

Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. Therefore, when you use the Services we will ask for your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver's license, passport or other identifying documents.

Republic and its affiliates are not and do not operate or act as a bank. Certain banking services are provided by BitGo Trust Company, a South Dakota-chartered trust company and registered money services business. BitGo Trust Company is not an FDIC member. Digital (crypto) assets and investment products are not insured by the FDIC, may lose value, and are not deposits or other obligations of BitGo Trust Company and are not guaranteed by BitGo Trust Company. Terms and conditions apply.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC